This is a Phase 1 ascending dose study evaluating a new CAR-T cell therapy called Descartes-08. This trial is sponsored by Cartesian Therapeutics.
In this trial, your own T-cells are removed from your body and modified by adding a Chimeric Antigen Receptor, making them CAR-T cells. These CAR-T cells are then designed to target the B–Cell Maturation Antigen (BCMA) which is expressed by some myeloma cells.
This trial is seeking 15 patients, and will give them increasing doses of the T-Cell therapy, and then monitor them for adverse side effects, followed by treatment response. Patients will be monitored for 12 months. Patients with prior CAR-T therapy and prior Anti-BCMA therapy are allowed in this trial.
In order to join, patients must have measurable myeloma that is double refractory to both a proteasome inhibitor (like Velcade) and an immunomodulatory drug (like Revlimid). Patients must have had at least 2 prior lines of therapy, and adequate vital organ function.
Click the link below to learn more about this study and see if you may be eligible. You can also call SparkCures with any questions at (888) 828-2206.